Iron Metabolism Disease (IRON)

Categories: Blood diseases, Endocrine diseases, Metabolic diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Iron Metabolism Disease

Summaries for Iron Metabolism Disease

MedlinePlus: 41 Iron is a mineral that our bodies need for many functions. For example, iron is part of hemoglobin, a protein which carries oxygen from our lungs throughout our bodies. It helps our muscles store and use oxygen. Iron is also part of many other proteins and enzymes. Your body needs the right amount of iron. If you have too little iron, you may develop iron deficiency anemia. Causes of low iron levels include blood loss, poor diet, or an inability to absorb enough iron from foods. People at higher risk of having too little iron are young children and women who are pregnant or have periods. Too much iron can damage your body. Taking too many iron supplements can cause iron poisoning. Some people have an inherited disease called hemochromatosis. It causes too much iron to build up in the body. Centers for Disease Control and Prevention

MalaCards based summary: Iron Metabolism Disease, also known as iron deficiency, is related to neurodegeneration with brain iron accumulation 1 and neurodegeneration with brain iron accumulation 3. An important gene associated with Iron Metabolism Disease is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Transport of inorganic cations/anions and amino acids/oligopeptides and Glucose / Energy Metabolism. The drugs Dopamine and Orange have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and lymph node, and related phenotypes are homeostasis/metabolism and liver/biliary system

Wikipedia: 75 Iron deficiency, or sideropenia, is the state in which a body lacks enough iron to supply its needs.... more...

Related Diseases for Iron Metabolism Disease

Diseases related to Iron Metabolism Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2570)
# Related Disease Score Top Affiliating Genes
1 neurodegeneration with brain iron accumulation 1 32.8 SLC11A2 FTL CP
2 neurodegeneration with brain iron accumulation 3 32.3 SLC11A2 IREB2 FTL CP ACO1
3 hemochromatosis, type 5 32.1 TFR2 HJV HFE FTL
4 friedreich ataxia 31.7 TFRC IREB2 HFE FTL ACO1
5 hemochromatosis, type 2b 31.6 TFR2 HJV HFE HAMP FTL
6 neurodegeneration with brain iron accumulation 31.6 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HFE
7 anemia, congenital dyserythropoietic, type ia 31.6 TFRC HJV HAMP EPO
8 hemochromatosis, type 3 31.4 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
9 hemochromatosis, type 4 31.1 TFRC TFR2 SLC40A1 SLC11A2 HJV HFE
10 vitamin b12 deficiency 30.9 HAMP EPO CRP
11 hemosiderosis 30.9 TFRC TFR2 TF SLC40A1 SLC11A2 HJV
12 thalassemia minor 30.8 HBB HAMP EPO
13 nutritional deficiency disease 30.8 TFRC TF SLC11A2 HJV HAMP EPO
14 porphyria cutanea tarda 30.6 TFRC TFR2 TF SLC40A1 HJV HFE
15 sickle cell disease 30.6 HBB G6PD EPO
16 hfe hemochromatosis 30.6 TF HFE
17 restless legs syndrome 30.5 TFRC SLC11A2 IREB2 HAMP FTL EPO
18 arthropathy 30.5 HJV HFE HAMP FTL CRP
19 polycythemia vera 30.4 TFRC HAMP EPO CRP
20 iron overload 30.3 TFR2 TF SLC40A1 SLC11A2 HJV HFE
21 polycythemia 30.3 TFRC HBB HAMP EPO CRP
22 alpha-thalassemia 30.3 TFRC HFE HBB HAMP G6PD EPO
23 alcohol use disorder 30.3 TF HFE CRP
24 thalassemia 30.3 TFRC TFR2 TF SLC40A1 HJV HFE
25 aceruloplasminemia 30.2 TFRC TFR2 SLC40A1 SLC11A2 IREB2 HJV
26 sickle cell anemia 30.2 TFRC HBB HAMP G6PD EPO CRP
27 neutropenia 30.2 TFRC EPO CRP CP
28 marasmus 30.2 TF CRP
29 asphyxia neonatorum 30.2 EPO CRP
30 hypogonadotropic hypogonadism 30.2 TFR2 SLC40A1 HFE HBB
31 pancytopenia 30.2 FTL EPO CRP CP
32 alpha-1-antitrypsin deficiency 30.2 IREB2 HFE HAMP
33 hemoglobin e disease 30.1 TFRC HBB
34 acute porphyria 30.0 IREB2 HFE HAMP ACO1
35 glucosephosphate dehydrogenase deficiency 30.0 HBB G6PD CRP
36 folic acid deficiency anemia 30.0 HAMP EPO CRP
37 pulmonary tuberculosis 30.0 SLC11A1 CRP CP
38 chronic pyelonephritis 29.9 EPO CRP
39 macrophage activation syndrome 29.9 FTL CRP
40 plasmodium vivax malaria 29.9 TFRC MT-CYB G6PD
41 anemia, autoimmune hemolytic 29.9 G6PD EPO CRP
42 retinal degeneration 29.9 TFRC SLC11A2 HEPH EPO CP
43 cutaneous porphyria 29.9 HFE HAMP
44 hemoglobin h disease 29.9 TFRC HBB HAMP
45 anemia of prematurity 29.8 TFRC HAMP EPO
46 hemoglobinopathy 29.8 TFRC TFR2 TF HFE HBB HAMP
47 gilbert syndrome 29.8 HFE G6PD CRP
48 splenic sequestration 29.8 HBB EPO
49 analbuminemia 29.8 TF EPO CRP
50 sideroblastic anemia 29.7 TFRC TFR2 SLC40A1 HJV HFE HAMP

Comorbidity relations with Iron Metabolism Disease via Phenotypic Disease Network (PDN):

Deficiency Anemia Pulmonary Hemosiderosis

Graphical network of the top 20 diseases related to Iron Metabolism Disease:

Diseases related to Iron Metabolism Disease

Symptoms & Phenotypes for Iron Metabolism Disease

MGI Mouse Phenotypes related to Iron Metabolism Disease:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.32 ACO1 CP CRP CYBRD1 EPO FTL
2 liver/biliary system MP:0005370 10.25 CP CYBRD1 EPO FTL HAMP HBB
3 nervous system MP:0003631 10.17 CP FTL G6PD HEPH HFE HJV
4 immune system MP:0005387 10.16 CP CRP EPO FTL G6PD HAMP
5 cardiovascular system MP:0005385 10.13 CP CRP EPO FTL G6PD HEPH
6 hematopoietic system MP:0005397 10.09 ACO1 CP EPO FTL G6PD HAMP
7 mortality/aging MP:0010768 9.8 ACO1 EPO FTL G6PD HAMP HBB
8 integument MP:0010771 9.28 HBB HEPH HJV IREB2 SLC11A1 SLC11A2

Drugs & Therapeutics for Iron Metabolism Disease

Drugs for Iron Metabolism Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2 Orange Approved Phase 4
Darbepoetin alfa Approved, Investigational Phase 4 209810-58-2
Ferrous gluconate Approved Phase 4 299-29-6
Halofantrine Approved Phase 4 69756-53-2 37393
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3
Mecobalamin Approved, Investigational Phase 4 13422-55-4
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 44475014
Ferrous succinate Approved Phase 4 10030-90-7
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
Ferric maltol Approved Phase 4 33725-54-1
Ferrous fumarate Approved Phase 4 141-01-5
Deferasirox Approved, Investigational Phase 4 201530-41-8 214348 5493381
Deferoxamine Approved, Investigational Phase 4 70-51-9 2973
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 4 83-88-5 493570
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 24892734 16212801 44176380
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6 1130
Cobalamin Experimental Phase 4 13408-78-1 6857388
Trichostatin A Experimental Phase 4 58880-19-6 5562 444732
28 Anesthetics Phase 4
29 Vitamin B6 Phase 4
30 Vitamin B 6 Phase 4
31 Teferrol Phase 4
32 Neurotransmitter Agents Phase 4
33 Caseins Phase 4
34 N-Methylaspartate Phase 4
35 Vitamin B3 Phase 4
36 Nicotinic Acids Phase 4
Vitamin B2 Phase 4
Chondroitin Phase 4 9007-27-6 14389182
39 Zinc Supplement Phase 4
40 Folate Phase 4
41 Vitamin B9 Phase 4
42 Vitamin B Complex Phase 4
43 Vaccines Phase 4
44 Vitamin B12 Phase 4
45 Vitamin B 12 Phase 4
46 Vitamin B1 Phase 4
47 Thiamin Phase 4
48 Blood Substitutes Phase 4
49 Anticoagulants Phase 4
50 Plasma Substitutes Phase 4

Interventional clinical trials:

(show top 50) (show all 1312)
# Name Status NCT ID Phase Drugs
1 Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia. Unknown status NCT00199277 Phase 4 i.v. iron sucrose;Oral iron
2 A Randomized, Double-blind, Multi-center Clinical Trial Prospectively Evaluating Iron Protein Succinylate Oral Solution in Treating Patients With Chronic Heart Failure and Iron Deficiency Unknown status NCT03344523 Phase 4 Iron protein succinylate oral solution
3 A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting Unknown status NCT01950247 Phase 4 Injectafer;SOC
4 the Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis Unknown status NCT03748043 Phase 4 Lactoferrin;Ferric Hydroxide Polymaltose
5 Effectiveness of Weekly and Daily Iron Supplementation for the Prevention of Iron-deficiency Anemia in Infants. Impact on Genomic Stability Unknown status NCT03359447 Phase 4 Weekly Ferrous Sulfate;Daily Ferrous Sulfate
6 Effectiveness of Iron Supplementation in the Second Year of Life for Prevention of Iron Deficiency Unknown status NCT00479102 Phase 4 Ferripel-3 - iron polysaccharide complex for prevention
7 Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy? Unknown status NCT03347513 Phase 4 triple attack therapy;Ferrous(II)-glycine-sulphate complex 567.7 mg capsules
8 Randomized Cross-Over Trial of Captafer® vs. Oral Iron Sulfate in the Treatment of Iron Deficiency Anemia in Patients With Inflammatory Bowel Disease Unknown status NCT02774057 Phase 4 Captafer®;Iron Sulfate
9 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Unknown status NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
10 Bovine Lactoferrin Versus Ferrous Sulphate In The Treatment Of Iron Deficiency Anemia During Pregnancy: A Randomized Controlled Trial Unknown status NCT03202615 Phase 4 F (ferrous sulphate)
11 Iron Deficiency as an Ignored Cause of Infertility Unknown status NCT04510870 Phase 4 Ferric Carboxymaltose Injection;NaCl infusion
12 Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial. Unknown status NCT02242188 Phase 4 Iron
13 The Role Of IV Iron (Ferric Carboxymaltose) And IM Vitamin B12 (Hydroxycobalamin) Supplementation In The Management Of Anaemic Prevalent Indian Hemodialysis Patients: A Parallel Group, Quadruple Blind, Placebo-Controlled, Pragmatic Randomized Control Trial With 2x2 Factorial Design Unknown status NCT04627181 Phase 4 Ferric carboxymaltose;Hydroxycobalamin;Placebo
14 Ferritin Screening And IRon Treatment for Maternal Anemia and Fetal Growth Restriction (FGR) Prevention - a Multi Centre Randomised Controlled Trial (RCT) Unknown status NCT04228627 Phase 4 Parentral Iron
15 The Impact of Treatment of Anaemia With Intravenous Iron on Haematological Values for Patients After Colorectal Surgery Unknown status NCT02999217 Phase 4 Iron isomaltoside;Saline
16 Double-Blind, Single-Center Interventional Trial To Evaluate The Effect Of Intravenous Iron Versus Placebo On Cerebral Dopamine Receptor Density In Non Anaemic Premenopausal Women With Low Ferritin Levels And Fatigue Unknown status NCT03305705 Phase 4 Iron Carboxymaltose;Sodium chloride 0.9%
17 Effektivität Der in Der Schwangerschaftsvorsorge routinemässig Angewandten Eisenprophylaxe Unknown status NCT02487719 Phase 4 Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia
18 a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year Unknown status NCT03171324 Phase 4 Iron Supplement
19 Treatment of Anemia in the 2nd Year of Life. Comparison of the Efficacy of Two Different Iron Preparations. Unknown status NCT00248716 Phase 4 Ferrous gluconate and iron polysaccharide complex
20 The Effect of a Nutrient Fortified Oat Drink on Iron, Zinc, Vitamin A, and Vitamin C Status Among Filipino Children Unknown status NCT01418898 Phase 4
21 Intravenous Iron Isomaltoside 1000 (Monofer®) Compared With Oral Iron in the Treatment of Postgastrectomy Anemia: An Open-label Randomized Controlled Trial Unknown status NCT03229954 Phase 4 iron isomaltoside (Monofer) intravenous infusion;Ferrous sulfate(Feroba-YOU) per oral
22 Intravenous Iron Treatment In Iron Deficient Patients With Idiopathic Pulmonary Arterial Hypertension Unknown status NCT01288651 Phase 4 Ferricarboxymaltose
23 Long-term Safety and Efficacy Study of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias Unknown status NCT02443545 Phase 4 Deferiprone
24 The Effect of Ferric Carboximaltose on Intra-myocardial Iron Load Assessed by Cardiac Magnetic Resonance in Patients With Heart Failure With Reduced Ejection Fraction (HFREF). Unknown status NCT03871699 Phase 4 Ferric carboxymaltose
25 Preoperative, Single-dose Intravenous Iron Formulation to Reduce Post-surgical Complications in Patients Undergoing Major Abdominal Surgery: a Pilot Randomised Control Trial (PIRCAS Trial - Pilot) Unknown status NCT03295851 Phase 4 Ferric carboxymaltose;Ferrous Fumarate
26 An Pilot Study to Assess the Efficacy of Intravenous Iron Isomaltoside 1000 (Monofer®) in the Management of Anaemia Associated With the Palliative Management of Oesophagogastric Adenocarcinoma Unknown status NCT01927328 Phase 4 Iron isomaltoside 1000
27 Combination With Intravenous Iron Supplementation or Doubling Erythropoietin Dose for Patients With Chemotherapy-induced Anaemia Inadequately Responsive to Initial Erythropoietin Treatment Alone Unknown status NCT02731378 Phase 4 Erythropoietins (EPO);Aggressive iron dextran supplementation;Sustained iron dextran supplementation
28 Sienna+® Injection Time Study: A Prospective Multicentre, Controlled Clinical Trial to Evaluate the Performance of Superparamagnetic Iron Oxide vs. Standard Technique as Tracer in Sentinel Node Biopsy Unknown status NCT02612870 Phase 4
29 Anemia Treatment in Inflammatory Bowel Disease: Predictive Factors of Response to Oral Iron Treatment Unknown status NCT02760940 Phase 4 oral liposomal iron
30 Multicenter Randomized Controlled Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion in the Treatment of Preoperative Anaemia in Colorectal Cancer Patients Unknown status NCT02243735 Phase 4 Ferrous fumarate;ferric(III)carboxymaltose
31 Does Intraoperative Intravenous Iron Sucrose Enhance Postoperative Oxygenation Profile in Total Arthroplasty Surgery? Unknown status NCT02544828 Phase 4 Iron Sucrose 200mg;placebo
32 Intraoperative IV Iron on the Postoperative Recovery of Red Blood Cell in Hip Arthroplasty Surgery Unknown status NCT04035902 Phase 4 Ferric carboxymaltose;control
33 Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia Unknown status NCT01084122 Phase 4 Iron sucrose
34 Effect of Intravenous Iron (Ferinject®) on Exercise Capacity and Quality of Life of Stable COPD Patients Unknown status NCT02416778 Phase 4 Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion
35 Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
36 A Randomized, Placebo Controlled, Double Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance Unknown status NCT00103753 Phase 4 deferiprone
37 Evaluation of the Efficacy in Decreasing Iron Absorption in Patients With Congenital Dyserythropoietic Anemia Type I by Treatment With LOSEC Unknown status NCT01795794 Phase 4 omeprazole
38 Phase IV Study of Oral Administration of Bovine Lactoferrin (bLf) to Prevent and Cure Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) Until Delivery in Hereditary Thrombophilia (HT) Affected Pregnant Women Completed NCT01221844 Phase 4 FerroGrad by Abbott
39 The Efficacy and Safety of Vitamin C for Iron Supplementation Therapy in Adult Patients With Iron Deficiency Anemia(IDA) Completed NCT02631668 Phase 4 ferrous succinate and vitamin C;ferrous succinate
40 Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. Completed NCT02031289 Phase 4 Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid
41 Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass Completed NCT02086968 Phase 4 Injectafer;Ferrous Sulfate tablets
42 A Single-center, Double-blinded, Randomized, 12 Week, Superiority Study in Infants and Young Children to Compare the Efficacy of NovaFerrum® Versus Ferrous Sulfate in the Treatment of Nutritional Iron Deficiency Anemia. Completed NCT01904864 Phase 4 elemental iron (NovaFerrum®);elemental iron (Ferrous Sulfate)
43 Lactoferrin Efficacy Versus Ferrous Sulfate in Treatment of Patients With Iron Deficiency Anemia Completed NCT04267653 Phase 4 Lactoferrin Bovine;Ferrous Sulfate
44 Rationale and Design of Ferric Polymaltose Hydroxide and Iron Sucrose Evaluation on Performance and Oxydative Stress in Patient With Iron deficIency and Stable Heart Failure Study Completed NCT04225728 Phase 4 Iron Sucrose IV;Ferric polymaltose hydroxide complex IM
45 Ferrous Bis-glycinate Versus Ferrous Glycine Sulfate for the Treatment of Iron Deficiency Anemia During Pregnancy Completed NCT02590224 Phase 4 Ferrous bis-glycinate;Ferrous glycine sulphate
46 A Prospective, Randomized, Multi-centered Trial to Compare the Efficacy and Safety of Intravenous Iron Sucrose (Venoferrum®) With Oral Iron Acetyl-transferrin Hydroglycerin (Bolgre®) in Pregnant Women With Iron Deficiency Anemia Completed NCT00802139 Phase 4 venoferrum(iron sucrose);Bolgre (Iron acetyl-transferase)
47 Low Dose Intravenous Versus Oral Iron for Iron Deficiency Anemia Starting Late in Pregnancy: A Randomized Controlled Trial Completed NCT00746551 Phase 4 Ferli-6® (Continental Pharm co., ltd.);Venofer® (Vifor AG, St. Gallen, Switzerland)
48 Treatment of Iron Deficiency Anaemia in Adults and Adolescents With Inflammatory Bowel Disease Using Ferrous Sulphate: Tolerance and Effects on Haemoglobin, Mood, Quality of Life and Fatigue Completed NCT01991314 Phase 4 Ferrous sulphate
49 Doubling the Iron Dose VS Single Dose Iron Supplementation to Prevent Iron Deficiency Anemia (IDA) in Twin Pregnant Women: A Randomized Controlled Trial Completed NCT03836703 Phase 4 Feroglobin single daily use;Feroglobin twice daily dose
50 Effectiveness of Intravenous Iron Treatment vs Standard Care in Patients With Heart Failure and Iron Deficiency: a Randomised, Open-label Multicentre Trial (IRONMAN) Completed NCT02642562 Phase 4 Ferric Derisomaltose

Search NIH Clinical Center for Iron Metabolism Disease

Cochrane evidence based reviews: iron metabolism disorders

Genetic Tests for Iron Metabolism Disease

Anatomical Context for Iron Metabolism Disease

Organs/tissues related to Iron Metabolism Disease:

MalaCards : Kidney, Heart, Lymph Node, Liver, Brain, Skeletal Muscle, Breast

Publications for Iron Metabolism Disease

Articles related to Iron Metabolism Disease:

(show top 50) (show all 47246)
# Title Authors PMID Year
New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer. 41
36430469 2022
The Association between Iron and Folic Acid Supplementation and Malaria Prophylaxis and Linear Growth among Children and Neonatal Mortality in Sub-Saharan Africa-A Pooled Analysis. 41
36364759 2022
Probability of non-compliance to the consumption of Iron Tablets in pregnant women in Indonesia. 41
36415291 2022
Elevated soluble transferrin receptor levels reflect increased erythropoietic drive rather than iron deficiency in pediatric sickle cell disease. 53 62
20486179 2010
Alpha 1-acid glycoprotein, hepcidin, C-reactive protein, and serum ferritin are correlated in anemic schoolchildren with Schistosoma haematobium. 53 62
20410090 2010
Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. 53 62
19624802 2010
Posttransplant anemia in solid organ recipients. 53 62
20303457 2010
Ceramide in suicidal death of erythrocytes. 53 62
20502001 2010
Iron stores, periodic leg movements, and sleepiness in obstructive sleep apnea. 53 62
20465018 2009
[Soluble tranferrin receptor in the biological diagnosis of iron deficiency. Report of 24 cases]. 53 62
20209848 2009
The role of transferrin receptor 1 and 2 in transferrin-bound iron uptake in human hepatoma cells. 53 62
19828835 2009
Ferric carboxymaltose in patients with heart failure and iron deficiency. 53 62
19920054 2009
Impact of socioeconomic and health related factors on the iron status of adolescent girls from two boarding schools in Southern Benin. 53 62
20306766 2009
[Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)]. 53 62
20232547 2009
Transferrin and ferritin response to bacterial infection: the role of the liver and brain in fish. 53 62
19428486 2009
Differential ferritin expression is associated with iron deficiency in coeliac disease. 53 62
19404207 2009
Influence of inflammation as measured by alpha-1-acid glycoprotein on iron status indicators among HIV-positive postpartum Zimbabwean women. 53 62
18506200 2009
Pediatric reference intervals for soluble transferrin receptor and transferrin receptor-ferritin index. 53 62
19718534 2009
Evaluation of iron deficiency as a nutritional adaptation to infectious disease: an evolutionary medicine perspective. 53 62
18949769 2009
Abnormal brain iron homeostasis in human and animal prion disorders. 53 62
19283067 2009
Early effects on T lymphocyte response to iron deficiency in mice. Short communication. 53 62
18825318 2009
Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency. 53 62
19147412 2009
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. 53 62
18815282 2009
Differing expression of genes involved in non-transferrin iron transport across plasma membrane in various cell types under iron deficiency and excess. 53 62
18830567 2009
The soluble transferrin receptor (TfR)-F-Index is not applicable as a test for iron status in patients with chronic lymphocytic leukemia. 53 62
19743956 2009
Suicide for survival--death of infected erythrocytes as a host mechanism to survive malaria. 53 62
19710527 2009
[Immune, inflammatory, and nutritional protein profile in children with iron deficiency in Côte d'Ivoire]. 53 62
19801348 2009
Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. 53 62
18987297 2009
Parenteral ascorbic acid in haemodialysis patients. 53 62
18827578 2008
Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia. 53 62
18974579 2008
Erythrocyte programmed cell death. 53 62
18720418 2008
[Old and new iron parameters in iron metabolism and diagnostics]. 53 62
18791966 2008
Facility factors dominate the ability to achieve target haemoglobin levels in haemodialysis patients. 53 62
18469314 2008
Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. 53 62
18613854 2008
Iron-independent phosphorylation of iron regulatory protein 2 regulates ferritin during the cell cycle. 53 62
18574241 2008
Soluble transferrin receptor and sTfR-F index for assessing concurrent iron deficiency in patients with chronic renal failure. 53 62
18317758 2008
[Expression of iron regulatory protein-2 and ferritins in intestinal mucosa of rats with iron deficiency]. 53 62
18549630 2008
Alteration of mRNA expression of molecules related to iron metabolism in adenine-induced renal failure rats: a possible mechanism of iron deficiency in chronic kidney disease patients on treatment. 53 62
18174266 2008
Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. 53 62
18279424 2008
Iron chelation by clinically relevant anthracyclines: alteration in expression of iron-regulated genes and atypical changes in intracellular iron distribution and trafficking. 53 62
18029550 2008
Bivariate mixture modeling of transferrin saturation and serum ferritin concentration in Asians, African Americans, Hispanics, and whites in the Hemochromatosis and Iron Overload Screening (HEIRS) Study. 53 62
18201677 2008
Potential roles of erythropoietin in the management of anaemia and other complications diabetes. 53 62
17645562 2008
Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia. 53 62
18212498 2008
Effect of erythropoietin on hepcidin, DMT1 with IRE, and hephaestin gene expression in duodenum of rats. 53 62
18306987 2008
Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure. 53 62
18094727 2008
Prognostic value of reticulocyte hemoglobin content to diagnose iron deficiency in 6-24-month-old children. 53 62
18971604 2008
The relationship between iron deficiency anemia and lipid metabolism in premenopausal women. 53 62
18004086 2007
Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. 53 62
17466092 2007
Molecular genetic studies of DMT1 on 12q in French-Canadian restless legs syndrome patients and families. 53 62
17510944 2007
Inflammation and iron deficiency in the hypoferremia of obesity. 53 62
17438557 2007

Variations for Iron Metabolism Disease

Expression for Iron Metabolism Disease

Search GEO for disease gene expression data for Iron Metabolism Disease.

Pathways for Iron Metabolism Disease

Pathways related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
Show member pathways
12.93 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
Show member pathways
12.23 SLC40A1 SLC11A2 HEPH CP
Show member pathways
11.89 SLC40A1 SLC11A2 SLC11A1 HEPH CP
Show member pathways
11.67 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
6 11.57 TFRC TF EPO CP
8 11.51 CP FTL IREB2 SLC11A2 SLC40A1 TF
9 10.56 TFR2 SLC40A1 SLC11A2 IREB2 ACO1
10 10.39 HJV HFE HAMP
Show member pathways
10.08 SLC40A1 CP

GO Terms for Iron Metabolism Disease

Cellular components related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 blood microparticle GO:0072562 9.86 TFRC TF HBB CP
2 recycling endosome GO:0055037 9.76 TFRC TF SLC11A2 HFE
3 basal part of cell GO:0045178 9.43 TF SLC11A2 HFE
4 HFE-transferrin receptor complex GO:1990712 9.32 TFRC TFR2 TF HJV HFE

Biological processes related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 iron ion homeostasis GO:0055072 10.23 FTL CYBRD1 CP HAMP HEPH HFE
2 cellular iron ion homeostasis GO:0006879 10.13 TFRC TFR2 TF SLC40A1 SLC11A2 SLC11A1
3 establishment of localization in cell GO:0051649 10.11 SLC40A1 SLC11A2 SLC11A1 IREB2 HAMP
4 acute-phase response GO:0006953 10.1 CRP EPO HAMP TFR2 TFRC
5 osteoclast differentiation GO:0030316 10.03 TFRC TF IREB2
6 response to iron ion GO:0010039 10.03 TFRC TFR2 SLC11A2 HFE HAMP CYBRD1
7 monoatomic ion transport GO:0006811 10.02 CP HEPH HFE SLC11A1 SLC11A2 SLC40A1
8 multicellular organismal iron ion homeostasis GO:0060586 10.02 HAMP HFE SLC11A1 SLC11A2 SLC40A1
9 copper ion transport GO:0006825 9.97 SLC11A2 HEPH CP
10 iron ion transmembrane transport GO:0034755 9.97 SLC40A1 SLC11A2 SLC11A1 HAMP
11 cellular response to iron ion GO:0071281 9.91 TFR2 TF HFE
12 positive regulation of peptide hormone secretion GO:0090277 9.89 TFR2 HFE
13 manganese ion transmembrane transport GO:0071421 9.88 SLC11A2 SLC11A1
14 transferrin transport GO:0033572 9.88 TFRC TFR2
15 manganese ion transport GO:0006828 9.87 SLC11A2 SLC11A1
16 citrate metabolic process GO:0006101 9.85 ACO1 IREB2
17 cadmium ion transmembrane transport GO:0070574 9.84 SLC11A1 SLC11A2
18 response to iron ion starvation GO:1990641 9.83 HFE HAMP
19 regulation of iron ion transport GO:0034756 9.81 TF HFE
20 iron ion transport GO:0006826 9.6 CP FTL HEPH IREB2 SLC11A1 SLC11A2

Molecular functions related to Iron Metabolism Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.99 HEPH HAMP CP
2 ferric iron binding GO:0008199 9.83 TF FTL
3 manganese ion transmembrane transporter activity GO:0005384 9.8 SLC11A2 SLC11A1
4 ferrous iron binding GO:0008198 9.8 TF HEPH FTL
5 ferrous iron transmembrane transporter activity GO:0015093 9.78 SLC40A1 SLC11A2
6 ferroxidase activity GO:0004322 9.76 HEPH CP
7 cadmium ion transmembrane transporter activity GO:0015086 9.73 SLC11A2 SLC11A1
8 aconitate hydratase activity GO:0003994 9.71 ACO1 IREB2
9 iron-responsive element binding GO:0030350 9.67 ACO1 IREB2
10 transition metal ion transmembrane transporter activity GO:0046915 9.56 SLC11A2 SLC11A1
11 transferrin receptor activity GO:0004998 9.46 TFRC TFR2
12 transferrin receptor binding GO:1990459 9.43 TF HJV HFE
13 iron ion transmembrane transporter activity GO:0005381 9.1 SLC40A1 SLC11A2 SLC11A1

Sources for Iron Metabolism Disease

8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
27 GO
28 GTR
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
36 LifeMap
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....